Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2013: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2012: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2011: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
Research Abstract |
We found that follistatin-like 1 (Fstl1) is protective against acute cardiac injury following ischemia-reperfusion (I/R). Administration of Fstl1 led to reduction of myocardial infarct size following I/R in vivo, which was accompanied by attenuation of inflammatory response and apoptosis in the ischemic heart. Furthermore, Fstl1 attenuated inflammatory reaction and apoptosis in cardiac myocytes by its ability to activate AMP-activated protein kinase pathway and inhibit bone morphogenetic protein-4 signaling pathway.
|